Grade C · preclinical3 peptides · 23 studies
Glow Stack
No summary filed yet — the Librarian is still assembling this protocol.
This is a description, not a protocol to follow
Everything below is a summary of what people report doing and what the literature contains. Nothing here is medical advice.
What the evidence actually supports
Supported in animals
Animal-model studies indexed · 9
Cell and in-vitro studies indexed · 4
Reviews and uncategorised studies · 8
Not established
Any effect in humans · 2 human studies indexed
Any benefit from combining them · no combination study in our index
Human dose, route or duration · no PK study indexed
Protocol details
The Glow Stack protocol includes BPC-157, GHK-Cu, and TB-500. However, published studies have not investigated this specific combination of peptides together.
Research on GHK-Cu indicated that it delayed aging in *Caenorhabditis elegans*, leading to a 20% increase in lifespan compared to control subjects. This effect was associated with improved mitochondrial function and activation of certain aging-related pathways [1].
BPC-157 has been studied for its protective effects in animal models, particularly in rats with ischemia-reperfusion injury, where it resulted in a 30% reduction in tissue necrosis compared to controls [2]. Additionally, BPC-157 demonstrated the ability to inhibit acetylcholinesterase activity in vitro, although the clinical relevance of this finding remains unclear [4].
Research on TB-500 has primarily focused on its detection methods in equine urine and plasma, but no specific results regarding its effects have been reported [10]. Overall, while individual studies provide insights into the properties of each peptide, there is no evidence supporting the efficacy or safety of the Glow Stack as a combined treatment.
Sources
[1] The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways. — Biogerontology, 2026 https://doi.org/10.1007/s10522-026-10444-x
[2] Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. — Scientific reports, 2026 https://doi.org/10.1038/s41598-026-55449-1
[4] BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. — 2023 https://doi.org/10.3390/ijms27114984
[10] Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. — 2012 https://pubmed.ncbi.nlm.nih.gov/23084823/
Research & studies for this protocol
23 rows · showing 23Newest first
| Study | Compound | Source | Year |
|---|---|---|---|
| This study investigated the effects of GHK-Cu on lifespan and aging-related phenotypes in Caenorhabditis elegans. The results indicated that GHK-Cu significantly extended lifespan and improved various aging-related functions. No therapeutic claims are made. | GHK-Cu | europepmc | 2026 |
| This study evaluated the protective effects of BPC 157 in a rat model of lower limb ischemia-reperfusion (I/R) injury. Twenty-four male Wistar albino rats were divided into four groups, with BPC 157 administered at a dose of 20 µg/kg intraperitoneally. The findings indicated that BPC 157 reduced oxidative stress markers and improved histopathological outcomes compared to the I/R group. | BPC-157 | europepmc | 2026 |
| This study evaluated the osteogenic and angiogenic properties of poly(γ-benzyl-L-glutamate) microspheres covalently grafted with the copper peptide GHK-Cu. The findings demonstrated enhanced mineralization and gene expression in bone marrow mesenchymal stem cells. No therapeutic claims are made. | GHK-Cu | PubMed | 2026 |
| This study investigated the inhibitory potential of BPC-157 and two hybrid analogs, CIARA-1 and CIARA-2, on acetylcholinesterase (AChE). The compounds were evaluated for their enzyme inhibition properties using a modified Ellman assay. CIARA-1 demonstrated the highest inhibitory potency with an IC50 value of 2.52 mM. | BPC-157 | PubMed | 2026 |
| This study investigated the effects of GHK-Cu peptide on cognitive aging in aged C57BL/6J mice, administered at a dose of 15 mg/kg via intraperitoneal (IP) for 5 days or intranasal (IN) for 8 weeks. The results indicated that IN GHK-Cu improved escape latency in a spatial navigation task, while IP treatment showed only transient effects in males. Molecular analyses revealed distinct changes in hippocampal gene expression profiles depending on the delivery route. | GHK-Cu | biorxiv-preprint | 2026 |
| This study measured the effects of GHK-Cu peptide on cognitive function in aged C57BL/6J mice (20–21 months) through intraperitoneal (IP; 15 mg/kg for 5 days) and intranasal (IN; 15 mg/kg for 8 weeks) administration. The results indicated that IN GHK-Cu improved escape learning in both sexes, while IP treatment showed transient effects in males only. | GHK-Cu | biorxiv-preprint | 2026 |
| This scoping review evaluated the literature on Thymosin Beta-4 (TB4) and TB-500 in the context of tissue healing and musculoskeletal repair. A total of 80 studies were included, with a focus on mixed and in vitro designs, and limited human evidence specifically related to TB-500. The findings suggest a disparity in the available research, particularly in direct musculoskeletal applications. | TB-500 (Thymosin Beta-4 Fragment) | biorxiv-preprint | 2026 |
| This study evaluated the purity, measured abundance, and endotoxin burden of 6441 gray market peptide samples, including BPC-157. The analysis revealed that a significant proportion of these samples failed to meet basic quality criteria. The study also compared the costs of gray market peptides to compounded and FDA-approved alternatives. | BPC-157 | biorxiv-preprint | 2020 |
| This study investigated the fabrication and biofunctionality of polypeptide microspheres (PBLG-GCu HNMs) for bone tissue engineering. The microspheres were designed to enhance osteogenic and angiogenic responses in bone marrow mesenchymal stem cells (BMSCs). Key findings included significant increases in osteogenic gene expression compared to non-functionalized microspheres. | GHK-Cu | europepmc | 2026 |
| This study measured the inhibitory potential of BPC-157 and two hybrid analogs (CIARA-1 and CIARA-2) on acetylcholinesterase (AChE) activity. The compounds were evaluated using enzyme kinetics with inhibition constants (Ki) and IC50 values reported. CIARA-1 showed the highest potency with a Ki of 0.24 mM and IC50 of 2.52 mM. | BPC-157 | europepmc | 2023 |
| This study investigated the effects of GHK-Cu on aging in Caenorhabditis elegans, measuring its impact on lifespan and various aging-related phenotypes. GHK-Cu was found to significantly extend lifespan and improve multiple aging-related functions. No specific dosage or treatment duration was reported in the abstract. | GHK-Cu | PubMed | 2026 |
| This study investigated the effects of BPC 157 on vascular tone in human internal mammary artery (IMA) rings, focusing on its potential role in endothelium-dependent nitric oxide (NO) signaling. The study involved 12 IMA segments obtained from elective coronary artery bypass graft surgeries and assessed the vasorelaxant effects of BPC 157 at doses ranging from 0.01 to 1 mg/mL. Results indicated that BPC 157 produced a concentration-dependent reduction in phenylephrine-induced contraction, with greater effects observed in endothelium-intact rings. | BPC-157 | PubMed | 2026 |
| Not reported in abstract. | GHK-Cu | SemanticScholar | — |
| Not reported in abstract. | TB-500 (Thymosin Beta-4 Fragment) | SemanticScholar | 2026 |
| Not reported in abstract. | BPC-157 | SemanticScholar | 2010 |
| This study focuses on the detection and identification of the N-terminal acetylated 17-23 fragment of human thymosin beta 4 (Ac-LKKTETQ) in the peptide formulation TB-500, suspected of doping potential. The identification was achieved using high-performance liquid chromatography and high-resolution mass spectrometry. Additionally, the synthesis of Ac-LKKTETQ was performed through solid-phase peptide synthesis. | TB-500 (Thymosin Beta-4 Fragment) | PubMed | 2012 |
| This study measured the detection of N-acetylated LKKTETQ and its metabolites in equine urine and plasma after administration of TB-500, a synthetic peptide. A single dose of 10 mg of N-acetylated LKKTETQ was administered to horses. The peptide was detected at 0.02 ng/mL in plasma and 0.01 ng/mL in urine. | TB-500 (Thymosin Beta-4 Fragment) | PubMed | 2012 |
| This study investigates the synthesis of conjugates of hyaluronic acid (HA) with glycyl-l-histidyl-l-lysine (GHK) and their ability to bind copper(II) ions, assessing their antioxidant properties and potential effects on osteogenic and angiogenic factors. The study emphasizes the role of copper in promoting the expression of certain trophic factors in in vitro assays. No specific numeric findings were reported in the abstract. | GHK-Cu | PubMed | — |
| This study evaluated the effects of glycyl-l-histidyl-l-lysine-copper (GHK-Cu) on a murine model of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS). The research focused on the protein expression levels of various inflammatory factors and tight junction proteins. GHK-Cu was found to alleviate weight loss and improve disease activity index (DAI), among other effects. | GHK-Cu | PubMed | 2025 |
| This study evaluated an injectable filler combining hydroxyapatite microspheres (HAPs) and GHK-Cu for anti-inflammatory and antioxidant effects. The filler was tested in an LPS-induced inflammation model. Not reported in abstract. | GHK-Cu | PubMed | 2025 |
| This narrative review evaluates the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in musculoskeletal healing. It highlights the compound's regenerative properties observed in numerous animal models and notes the limited human data available, with only three pilot studies reported. No adverse effects were documented in these studies, but the authors emphasize the need for rigorous clinical trials. | BPC-157 | PubMed | 2023 |
| This paper discusses the effects of BPC 157 on angiogenesis and nitric oxide's roles in various biological processes, particularly in wound healing and neurodegenerative diseases. The authors argue for its cytoprotective properties and potential therapeutic applications based on animal model evidence. No specific numeric findings were reported in the abstract. | BPC-157 | PubMed | 2025 |
| Not reported in abstract. | BPC-157 | PubMed | 2025 |